300573.SZ SHZ
Shenyang Xingqi Pharmaceutical Co.,Ltd
1W: -1.2%
1M: -4.8%
3M: -13.5%
YTD: -48.5%
1Y: -39.7%
3Y: -49.1%
5Y: -10.4%
¥36.43 ($5.43)
+0.74 (+2.07%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$2.1B
+5.1% ▲
5Y CAGR: +20.1%
Total Liabilities
$534M
+60.1% ▲
5Y CAGR: +14.0%
Shareholders Equity
$1.6B
-5.7% ▼
5Y CAGR: +22.9%
Cash & Investments
$370M
-23.0% ▼
5Y CAGR: +49.3%
Total Debt
$209M
+189.2% ▲
5Y CAGR: +18.4%
Net Debt
-$161M
+60.5% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $37M | $686M | $515M | $480M | $370M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Cash & ST Investments | $37M | $686M | $515M | $480M | $370M |
| Net Receivables | $158M | $183M | $195M | $252M | $281M |
| Inventory | $68M | $92M | $122M | $136M | $154M |
| Other Current Assets | $30M | $0 | $32M | $0 | $472K |
| Total Current Assets | $294M | $984M | $865M | $905M | $830M |
| Property, Plant & Equip. | $528M | $549M | $696M | $870M | $992M |
| Goodwill & Intangibles | $45M | $74M | $123M | $188M | $194M |
| Long-Term Investments | $17M | $22M | $12M | $13M | $10M |
| Other Non-Current Assets | $47M | $28M | $63M | $9M | $79M |
| Total Non-Current Assets | $671M | $702M | $918M | $1.1B | $1.3B |
| Total Assets | $966M | $1.7B | $1.8B | $2.0B | $2.1B |
| — Liabilities — | |||||
| Accounts Payable | $6M | $13M | $19M | $18M | $18M |
| Short-Term Debt | $80M | $100M | $0 | $70M | $200M |
| Deferred Revenue | $116M | $138M | $2M | $0 | $0 |
| Other Current Liabilities | $121M | $22M | $19M | $167M | $27M |
| Total Current Liabilities | $212M | $267M | $152M | $260M | $461M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Other Non-Current Liab. | -$30M | $68M | $0 | $0 | $0 |
| Total Non-Current Liabilities | $59M | $76M | $78M | $74M | $73M |
| Total Liabilities | $272M | $342M | $231M | $334M | $534M |
| — Equity — | |||||
| Common Stock | $82M | $88M | $89M | $125M | $175M |
| Retained Earnings | $286M | $435M | $567M | $614M | $464M |
| Accumulated OCI | $64M | $95M | $119M | $0 | $0 |
| Total Stockholders Equity | $682M | $1.3B | $1.6B | $1.7B | $1.6B |
| Total Liabilities & Equity | $966M | $1.7B | $1.8B | $2.0B | $2.1B |
| — Key Metrics — | |||||
| Total Debt | $80M | $111M | $14M | $72M | $209M |
| Net Debt | $43M | -$575M | -$502M | -$408M | -$161M |
| Total Investments | $17M | $22M | $12M | $13M | $10M |